Using gene therapy technologies to study and treat skeletal muscle

Presented by Associate Professor Paul Gregorevic, The University of Melbourne

A/Prof Gregorevic is Head of the Laboratory for Muscle Research and Therapeutics, and Deputy Director of the Centre for Muscle Research at The University of Melbourne, a Senior Research Fellow of the NHMRC, and the President of the Australasian Gene and Cell Therapy Society (AGCTS).

His research employs gene delivery technologies and skeletal muscle as a model system to a) investigate the mechanisms underlying the regulation of cell growth, adaptation and remodelling, b) examine the role of muscle in the maintenance of health, and c) develop muscle-directed interventions for the treatment of frailty associated with heritable and acquired illness, and advancing age.

He received his Ph.D. from The University of Melbourne (2001), before completing post-doctoral training at The University of Melbourne (2001-2002) and The University of Washington (2002-2008). From 2008-2018, he was Head of the Laboratory for Muscle Research and Therapeutics, and Director of the Recombinant Viral Vector Facility at the Baker Heart and Diabetes Institute. In 2018, he was appointed to his current role and relocated his team to support the establishment of the Centre for Muscle Research at The University of Melbourne.